YM 90709

Key Product Details

Product Description

YM 90709 is a novel, selective inhibitor of interleukin-5 (IL-5) (IC₅₀ = 0.45 - 1 mM). Inhibits IL-5-prolonged eosinophil survival and IL-5-induced tyrosine phosphorylation of JAK2 without inhibiting GM-CSF-mediated effects. Inhibits antigen-induced eosinophil and lymphocyte recruitment in rat airways in vivo, without affecting peripheral blood or bone marrow leukocytes.

Licensing Information

Sold with the permission of Astellas Pharma Inc.

Product Specifications for YM 90709

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for YM 90709

The following data is based on the product molecular weight 359.43.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	5.56 mL	27.82 mL	55.64 mL
2.5 mM	1.11 mL	5.56 mL	11.13 mL
5 mM	0.56 mL	2.78 mL	5.56 mL
25 mM	0.11 mL	0.56 mL	1.11 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Morokata Effect of a novel interleukin-5 receptor antagonist, YM-90709 (2,3-dimethoxy-6,6-dimethyl-5,6-dihydrobenzo[7,8]indolizino[2,3-b]quinoxaline), on antigen-induced airway inflammation in BN rats. Int.Immunopharmacol. 2004 PMID: 15182727
• Morokata Effect of a novel interleukin-5 receptor antagonist, YM-90709, on antigen-induced eosinophil infiltration into the airway of BDF1 mice. Immunol.Lett. 2005 PMID: 15790522
• Morokata Characterization of YM-90709 as a novel antagonist which inhibits the binding of interleukin-5 to interleukin-5 receptor. Int.Immunopharmacol. 2002 PMID: 12469943

Product Documents for YM 90709